Sedana Medical receives market approval in Italy
Sedana Medical AB (publ) has received market approval for Sedaconda[®] (isoflurane) for inhaled sedation in intensive care in Italy, bringing the number of European countries where the company’s therapy is approved to 17.“With this approval in Italy, we have now received market approval in 17 European countries, and are eagerly awaiting approval also in the UK during 2023. These approvals allow us to offer the first and only registered therapy for inhaled sedation of mechanically ventilated patients in intensive care", says Johannes Doll, President and CEO of Sedana Medical. Sedaconda[®] (